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ABSTRACT 
 
The latest United Kingdom (UK) strategy for rare diseases emphasises the need to empower affected 
populations to improve diagnosis, intervention, and coordination of care. Families who have a child with a rare 
chromosome disorder (RCD) are a challenging group to include. We report the findings of two large-scale 
surveys, undertaken by the UK RCD Support Group Unique, of these families’ experiences over a ten year 
period. Seven stages of the patient journey were examined. From pre-testing, through diagnosis, genetics 
consultation, clinical follow-up and peer support. Overall, 1,158 families replied; 36.4% response rate (2003) 
and 53.6% (2013). Analysis of responses identifies significant differences (p<0.001) over time with a 
decrease in results reported face-to-face (76-62%), doubling by telephone (12-22%), improved explanation of 
chromosome disorder (57-75%), and increased signposting to peer support group (34-62%). However, 
conduct of the consultation raises a number of important questions. Overall, 28 aspects of the patient journey 
are recognised as requiring improvement; only 12/28 are currently incorporated in UK service specifications. 
Involvement of RCD families has identified key service improvements. This approach can empower those 
affected by such extremely rare disorders, and also enable professionals to design improved services in 
partnership with ‘expert families’. Further surveys are planned. 
 
 
KEY WORDS 
Families' experiences, clinical genetics services, rare chromosome disorders, national surveys, patient 
reported outcomes (PROs), evidence-based clinical guidelines 
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1.  INTRODUCTION 
 
The United Kingdom (UK) Strategy for Rare Diseases places a strong emphasis on empowering those 
affected by rare diseases in order to improve diagnosis, intervention, and coordination of care in genetics 
services 1.  Although the strategy was published in late 2013, implementation plans are still being developed 
for England in 2017 with a view to being fully actioned in 2020.  It is acknowledged that this will require 
“strengthening the mechanisms and opportunities for meaningful and sustained patient involvement in rare 
disease service provision”. 
 
An important and challenging group to consider when involving those affected by rare diseases will be 
children with a rare chromosome disorder (RCD).  In the UK, it is estimated that at least 300-500 children 
are born every year with one of a range of RCDs, widely spread geographically 2.  In comparison to more 
common and well-studied chromosome disorders like Down syndrome, there is far less information 
available on the natural history or prognosis for these rare diseases (<5 per 10,000 births) 3.  Their extreme 
rarity means RCD cases can be particularly challenging for genetics services because, in addition to 
communicating a laboratory diagnosis, professionals also need to support families who frequently 
experience severe distress combined with high levels of uncertainty 4.  In such a situation, service providers 
must ensure that parents understand the diagnosis, help families identify effective coping strategies, and 
address the lack of available evidence 5 6.  To date, little is known about the experiences of these families, 
or the degree to which Clinical Genetics Services currently meet their needs.  This is an important gap, 
since the UK strategy emphasises that successful implementation will require “recognising patient groups 
as key partners” to develop care pathways that incorporate “best practice from the user perspective” 1. 
 
Patient-reported outcomes for Clinical Genetics Services are still in their infancy 7.  Over the last decade 
some developments have occurred, largely driven by the extension of clinical genetic services from 
diagnosing conditions that are exclusively genetic in nature to investigating genetic components for more 
common diseases 8, with increased knowledge about the contribution of genetic factors to a range of 
common diseases 9.  Comprehensive data are not yet available for RCDs although it is anticipated that, in 
time, the new National Congenital Anomaly and Rare Disease Registration Service established by Public 
Health England will fill this gap in knowledge 10, with projects such as the Sanger DECIPHER database 11 
and the Unique registry/database and information guide service 12 also contributing to an improved 
knowledge base.  Currently, there is no European Reference Network (ERN) specific to RCDs despite pan-
European efforts to create one.  However, the UK-led ERN-Ithaca for intellectual disability and congenital 
malformations will include RCDs with family support group representation and promises to be a channel 
through which the experiences of RCD families can be improved. 
 
For chromosome disorders, technological developments such as the introduction of microarray-based 
comparative genomic hybridisation (microarray analysis) techniques have meant that chromosome 
abnormalities which were formerly too small to be detected by conventional karyotyping can now be 
identified.  Although this has significantly improved sensitivity for detection of clinically relevant genomic 
imbalances, it has also increased the need for comprehensive genetic counselling to ensure accurate 
clinical interpretation 13.  In the case of RCDs, clinical interpretation will still face a high level of uncertainty 
about each affected child’s health, potential cognitive development, and life span even after there is a 
definitive diagnosis 14-16. 
 
In this paper, we present the findings of two large scale surveys which investigated the experiences of UK 
families who have a child with a RCD over the period 2003 – 2013.  We examined the entire care pathway 
including provision of pre-test information, diagnosis of RCD, genetic counselling, provision of follow-up 
information and ongoing support.  Analysis of responses at different time-points is used to reveal trends 
and changes over time.  The findings should hopefully enable best practice from the user perspective to 
be more effectively integrated into the implementation phase of the UK Strategy for Rare Diseases. 
 
 
1.1  Objectives 
 
The study had three main objectives: 
 
1. to examine RCD families’ experiences along the entire care pathway; 
2. to compare differences over ten years and identify positive or negative changes over time; and 
3. to recommend improvements to service provision for this important patient group. 
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2.  METHODS 
 
2.1  Survey Overview 
 
Two surveys were undertaken using a detailed questionnaire designed by Unique, a UK-based Rare 
Chromosome Disorder Support Group.  This support group has over 15,300 member families, representing 
over 17,000 individuals affected by RCDs, in over 100 countries worldwide, with around 1500 new families 
registering annually 17.  The process for designing the questionnaire is described in Supplementary file 1.  
The first survey was undertaken in March 2003 and the second in May 2013.  Both surveys were limited to 
members with at least one surviving child with RCD and a valid UK address.  The 2013 survey recruited a 
different cohort of families who joined the group after March 2003.  Questionnaires were identical, except 
for some questions in 2013 relevant to the introduction of microarray analysis 18.  The layout of 
questionnaires was designed to adhere to good practice and minimise the possibility of unreliable data or 
systematic missing responses19.  Questionnaires in 2003 were pre-printed and posted out to families while 
questionnaires in 2013 could be completed online or printed off and returned by post; responses were 
anonymous.  The initial invitation in 2013 was followed by two email reminders. 
 
2.2  Questionnaire Content 
 
Questionnaires collected background information on the family.  Respondents were then asked about their 
experiences during different stages of the patient journey (see Table 1).  A separate question asked families 
to rate the quality of the overall service from a user perspective in terms of the overall service received on 
a ten-point Likert scale ranging from 1 (worst) to 10 (best), and how helpful overall the genetics counselling 
service has been since their first appointment (4 categories ranging from ‘not very helpful’ to ‘very 
helpful’).  Finally, respondents were invited to give free text descriptions of their experiences of diagnosis 
and genetic counselling.  A copy of the 2003 postal questionnaire is provided in Supplementary file 2. 
 
2.3 Data Analysis 
 
Numerical data were summarised using mean and SD or median and range, depending on data distribution.  
Analysis was based on completed question responses.  There was no imputation of missing data, although 
we investigated to assess as far as is possible that missing data were missing completely at random.  
Certain descriptive variables with multiple response categories were dichotomized before analysis e.g. 
whether person communicating diagnosis was ‘genetics professional’ or ‘non-genetics professional’, 
whether the method of communicating was ‘in person face-to-face’ or ‘indirect by phone, letter etc.’.  For 
comparison of baseline and 2013 responses, chi-square tests were performed for categorical variables and 
t-tests or Mann–Whitney U tests for continuous variables.  95% confidence intervals were estimated 
together with the significance level of observed differences. In addition, some 2013 survey responses were 
analysed separately for cases diagnosed before and after the introduction of microarray tests in 2008.  
Stata (version 13) was used for all analyses.  Statistical significance was set at p=0.001 level. 
 
2.4  Recommended Improvements 
 
A list of recommended improvements was compiled by knowledgeable family members with direct 
personal experience of RCD, as well as a clinical geneticist and genetics laboratory scientists.  
Recommendations were based on analysis of data extracted from the questionnaire responses (with 
detailed examination of levels, significant changes or lack of a significant difference over time). 
 
 
3.  RESULTS 
 
3.1  Respondents  
A total of 583/1600 families responded to the 2003 survey (36.4% response rate).  In 2013, of 584 
responses received; 9 families not resident in the UK were excluded, leaving a total of 575/1072 
questionnaires for analysis (53.6 % response rates). 
 
Respondent characteristics were similar in the two groups.  Mean age was 42.3 years in 2003 and 43.0 
years in 2013.  Questionnaires were mainly completed by mothers, although this proportion fell over time 
from 92.3% to 85.9% in 2013.  The majority described themselves as White British/ White European, 
although ethnic minority respondents doubled over the period from 4.8% to 8.5%.  Most families had only 
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one child with a RCD, with this figure rising over the ten years from 86.1% to 92.3%.  A small minority of 
families had lost a child with a RCD at or after birth; this figure had reduced over time from 6.5% in 2003 
to 2.2% in the 2013 sample. 
 
3.2  Rating of service received 
When asked how helpful the genetics counselling service had been since their first appointment, Figure 
1a shows views were fairly evenly spread across the four categories ranging from ‘not very helpful’ to 
‘very helpful’, although the most common response was ‘had no more contact’.  The percentage rating a 
service as ‘not very helpful’ did not alter over time; it was 18.7% (95% Confidence Interval (CI): 15.1 - 
22.7) in 2003 and 15.0% (95% CI: 11.6 - 19.0) in 2013 (p=0.161). 
 
When asked to rate overall service quality on a ten-point scale, average scores rose from 6.37 [SD 2.63] 
in 2003 to 7.00 [SD 2.52] in 2013.  Figure 1b shows mean scores for different professional groups (i.e. 
genetics doctors, genetics counsellors, and genetics nurses).  In 2013, scores were 7.1 (95% CI 6.9, 7.3), 
6.5 (6.0, 7.1), and 6.6 (5.7, 7.5) respectively.  Therefore, using an unpaired t-test, the genetics doctors 
scored statistically significantly higher than the genetics counsellors.  Comparison of the genetics doctors 
with the nurses, and of the counsellors with nurses, were not statistically significant.  
 
3.3  Families’ experiences over ten years 
Families’ experiences of services over time are presented in Table 2. 
 
1: Pre-testing process: In 2003 only 70.7% (95% CI: 66.4 - 74.7) of families reported that they had been 
informed that their child's chromosomes were going to be tested.  In 2013, this figure was slightly higher at 
73.2% (95% CI: 68.6 - 77.5) but showed no significant improvement over the ten years (p=0.404). 
 
2: Test result communication: In 2003, test results were far more likely to be communicated by a 
paediatrician (64.5% (95% CI: 60.3 - 68.5)) than a genetic specialist (23.8% (95% CI: 20.2 - 27.5)).  By 
2013, results were almost equally likely to be communicated by a genetic specialist (49.0% (95% CI: 44.3 
- 53.7)) or a paediatrician (45.0% (95% CI: 40.3 - 49.7)).  Results were rarely reported by other 
professionals e.g. GPs, genetic nurses, obstetricians, health visitors. 
 
Table 2 indicates that, over the ten year period, it has become significantly less likely (p<0.001) that parents 
will be informed in person about their child’s chromosome disorder, although even in 2013 the majority still 
stated that they were told in person (62.7% (95% CI: 58.2, 67.1)) versus 76.1% (95% CI: 72.4 - 79.6) in 
2003.  During the same period, communication by telephone doubled from 12.2% (95% CI: 9.6 - 15.2) 
to 22.1% (95% CI: 18.4 - 26.1) in 2013, and by 50% for letters from 10.1% to 14.4%.  Similar trends, 
away from telling parents in person, are observable for both professional groups (i.e. paediatricians and 
genetic specialists). 
 
Possibly linked to this trend, responses indicate a shift towards families receiving their test result at home.  
This has risen significantly (p<0.001) from 17.1% (95% CI: 14.0, 20.6) in 2003 to 27.1% (95% CI: 22.9, 
31.7) in 2013.  At the same time, there has been an increase (p=0.006) in test results being communicated 
in a genetics centre from 8.7% (95% CI: 6.5 - 11.5) to 14.4% (95% CI: 11.1, 18.2); and a significant drop 
(p<0.001) in parents receiving information on the ward after birth or on the children’s ward (28.5% (95% 
CI: 24.6 - 32.5) vs. 14.7% (95% CI: 11.4 - 18.4).  Throughout, one in four families continued to receive 
their test results in a doctor’s surgery (26.7% vs. 23.6% in 2013) and one in ten in a child development 
centre (11.3% vs. 11.5%).  The proportion who are told in private has not changed significantly (p=0.697) 
over this period; 80.2% (95% CI: 76.5 - 83.5) in 2003 and 81.1% (95% CI: 77.2 - 84.8) in 2013.  Services 
did not always ensure that support was available from a spouse/partner, relative or friend when imparting 
this life-changing information.  In 2003, one quarter of respondents (23.1% (95% CI: 19.5 - 26.9)) were 
on their own when they received the diagnosis; rising slightly (p=0.082) to 28.0% (95% CI: 23.8 - 32.4)) 
in 2013.  In addition, 47.3% (95% CI: 42.9 - 51.7)) said that their affected child had been present in 2003, 
and 46.1% (95% CI: 41.3 - 50.9)) in 2013, indicating no significant change (p=0.710). 
 
3: Referral to a genetic specialist: Table 2 shows that the proportion of families receiving genetic 
counselling has decreased slightly (p=0.031) from 58.4% (95% CI: 54.2 - 62.5)) in 2003 to 52.0% (95% 
CI: 47.7 - 56.2)) in 2013.  For families informed about their child's test result by a non-geneticist (i.e. 
paediatrician, GP etc.) likelihood of referral to a genetic specialist has not increased (p=0.322), with two 
out of ten not offered a referral; 22.3% (95% CI: 18.4 - 26.7)) in 2003 and 19.3% (95% CI: 14.9 - 24.2)) 
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in 2013.  In families where a second child was diagnosed with an RCD, this figure remains similar (22.7% 
vs. 21.7% in 2013). 
 
Once referred, the waiting time for an appointment was over 3 months with a slight non-significant 
(p=0.105) increase over time; 95.7 days in 2003 (95% CI: 83.6 - 107.7)) and 115.0 days (95% CI: 94.4 - 
135.7)) in 2013.  For a medical geneticist the time has increased from 103.5 days to 172.1 days and for a 
genetic counsellor from 118 days to 199.1 days.  However, for genetic nurses waiting times have fallen 
from 118 days to 75.6 days.  In cases where a definitive diagnosis could not be made at the time of the 
appointment (15%), further tests are increasingly likely to be ordered; 43.1% of such cases in 2003 and 
60.0% in 2013.  These further tests produce a change in the provisional diagnosis in one in ten cases 
(11.6% in 2003 and 9.9% in 2013). 
 
4: Conduct of genetic consultation: Table 2 shows that most respondents considered they had been 
informed of their child’s condition in a sensitive manner; with a slight rise (p=0.014) from 66.9% (95% CI: 
62.6 - 70.9)) in 2003 to 74.1% (95% CI: 69.8 - 78.2)) in 2013.  There appear to be consistent differences 
between the perceived sensitivity of different professional groups; for genetic professionals, 81.6% in 
2003 and 86.2% in 2013 were viewed as providing the information sensitively, 63.3% and 67.7% of 
paediatricians respectively, and 43.8% vs. 44.0% of other clinicians. 
 
The conduct of consultations was explored in some detail.  Although genetic specialists always 
introduced themselves (>98% consultations), families were not always told how long the consultation 
would take (45.6% vs. 38.1% in 2013) or asked what information they already had (24.7% vs. 24.3% in 
2013 not asked), and half were not asked how detailed they would like information provided to be (56.5% 
vs. 54.4% in 2013).  Almost half of respondents thought the genetic specialist did not seem to know 
about them and their family (49.1% vs. 42.3% in 2013), one in five said that a family genetic history was 
not taken (20.7% vs. 21.0% in 2013), and one third said that there had been no physical examination of 
their child (37.4% vs. 31.9% in 2013).  The risk of having another baby with an RCD was not always 
explained, with evidence of a decline over time and variation between professionals; medical geneticists 
(11.8% vs. 20.0% in 2013 did not explain), genetic counsellors (19.0% vs. 32.1%), and genetic nurses 
(27.8% vs. 30.0%).  
 
Provision of a written summary following the genetic consultation is considered to be good practice 20.  In 
2003, written summaries were provided by 69.0% of medical geneticists, 50.7% of genetics counsellor and 
43.8% of genetics nurses.  By 2013, although figures had risen to 81.0%, 65.3% and 65.4% respectively, 
they were still not provided for all as routine practice.  On average, families had to wait one month to 
receive a summary, but some waited as long as 6 months; in 2013 longer delays were reported.  The 
written information provided was considered easy to understand by almost all recipients (93.0% in both 
2003 and 2013). 
 
5: Genetic and clinical information provision: Although most respondents could understand the information 
provided (92.7% in 2003 vs. 89.7% in 2013), the majority considered they had not been given enough 
information about their child’s condition.  Table 2 shows this did not change significantly (p=0.093) over 
time; 69.4% (95% CI: 65.2 - 73.4) in 2003 and 64.3% (95% CI: 59.6 - 68.8) in 2013.  Responses were 
not affected by the introduction of microarray analysis, with 66.4% pre-2008 and 61.4% post-microarrays 
reporting a need for more information.  In terms of the content of the information provided, although the 
majority of families were told which chromosome numbers were involved this has not increased 
significantly (p=0.067); 78.5% (95% CI: 74.6 - 82.0) were told in 2003 and 83.3% (95% CI: 79.4 - 86.7) 
in 2013.  However, explanation of the type of chromosome disorder in a clear and understandable way 
has improved significantly (p<0.001) rising from 57.2% (95% CI: 52.8 - 61.6) in 2003 to 75.1% (95% CI: 
70.7 - 79.1) in 2013.  Similarly, although a significant proportion of families are not given the karyotype, 
this has decreased over time (44.4% in 2003 falling to 34.0% in 2013).  
 
Virtually all respondents (95%) said they would have liked a copy of the genetics laboratory report.  
Although this was not provided in the majority of cases, there is evidence that families are increasingly 
likely to be given a copy.  In 2003, 71.1% were not given a copy, compared to only 48.6% in 2013.  
However, when laboratory reports were provided, only half included a suitable explanation of the medical 
or technical terms used, with no evidence of improvement over time (52.2% in 2003 vs. 50.2% in 2013). 
 
In terms of the clinical prognosis, nearly one in three respondents said that they were not told the possible 
effects on their child of the chromosomal abnormality (30.1% vs. 28.7% in 2013). In cases where this is 
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provided, accuracy appears to have improved over time e.g. for genetic nurses from 68.3% to 75.7% 
considered accurate in 2013. 
 
6: Genetic service follow-up: Although most families were offered a further meeting to discuss their child’s 
chromosome disorder, one third reported that they were not.  There was a slight but non-significant 
(p=0.158) improvement over time.  In 2003, 35.2% (95% CI: 31.1 - 39.5) were not offered a further 
meeting, falling to 30.9% (95% CI: 26.6 - 35.5) in 2013.  Linked to this, only a minority of families said 
they were told how the genetic counselling service could help them in the future; 28.9% in 2003 and 
31.0% in 2013. 
 
7: Signposting to peer support: Signposting of families by all specialists to some form of peer support 
group has risen significantly, from 34.8% of families in 2003 to 58.7% in 2013.  Respondents were 
increasingly likely to be signposted to Unique (26% in 2003 rising to 67% in 2013).  Only a small number 
of respondents stated that the genetic specialist tried to put them off contacting other affected families 
(7.3% in 2003 and 3.9% in 2013).  Nevertheless, very few respondents (7% in both time periods) reported 
that they were offered any help to contact other RCD families. 
 
3.4 Recommended improvements identified 
 
Table 3 lists the recommended improvements identified by experts based on survey responses.  The 
penultimate column identifies which are included in the NHS England service specification for organisations 
funded to provide specialised medical genetics services 21.  This indicates that 12 out of 28 
recommendations identified by the present study are already included in service specifications.  However, 
aspects which are missing include: a) education of non-clinical professionals; b) recommended speed of 
testing; c) six practical recommendations for communication of test results; d) need to indicate waiting time 
for referral to a genetics expert; e) five specific recommendations for conduct of consultation with genetics 
expert.  For section f), all recommendations identified by the current study are included in the service 
specification.  The final column shows levels achieved as reported by respondents for selected 
recommendations included in the service specification.  These range from 36% to 80%. 
 
4.  DISCUSSION 
 
The necessity for patient reported outcomes (PROs) in clinical genetics services has been identified in a 
recent review 7.  However, provision of services to families who have a child with a RCD is acknowledged 
to be exceptionally challenging 4-6.  There is also limited research evidence.  A review of research into 
clinical genetics services and the patient perspective which identified 102 articles 22 found only one focused 
on these families 3.  The recommendations identified in the current study are novel because they are based 
on the real-life experiences of over one thousand families living with RCDs.  As PROs become more 
important in performance management and funding of health services 7, sustained capture of the 
experiences of such families will be a key challenge 1.  Although a recommendation for ‘sustained patient 
involvement in rare disease service provision’ was embedded in the UK strategy for rare diseases, the 
overall strategy implementation plan for England has only recently been announced 23.  
 
The large scale surveys reported here show that, although families’ rating of service quality has improved 
over time, key aspects of the ‘patient journey’ have not and require improvement.  Although agreement on 
key PROs for genetic services is generally acknowledged to be challenging for RCD cases 7 24, our surveys 
do highlight a number of simple improvements which might be easily introduced and which are indicated 
elsewhere.  For example, a review of guidelines from 18 organisations in six countries on communication 
of genetic information to families concluded that there was a significant gap in terms of the professional’s 
role in assisting clients to find options for continued support 25.  This is a key finding identified from our 
surveys.  Our results also echo evidence from US research which found that parents of children with RCDs 
were largely disappointed in the counselling they received, although this was only a small-scale study 3.   
 
Although international guidelines for clinical genetics professionals largely cover the professional-client 
relationship, including respect for the client, maintaining confidentiality, and enabling clients to make 
informed independent decisions 26 27, they do not include more practical PROs such as those reported in 
the present study.  Other recommendations, such as those produced by Rare Disease UK (a project of the 
charity Genetic Alliance UK) mostly concentrate on higher level activities (e.g. commissioning and planning 
of services for rare diseases) with some general recommendations to improve information and support 28.  
More recent recommendations for reporting the results of diagnostic genetic tests primarily focus on 
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providing patients with information on how to manage their own condition, something which is less relevant 
for families of children with RCDs 29.  However, the most recent service specification for organisations 
providing specialised NHS medical genetics services does include some, but not all, of the 
recommendations identified in the present study 21. 
 
Meanwhile, international evidence has emerged of large variations in clinical genetics practice, leading to 
an increased interest in defining the quality of services and improving delivery models 30-32.  Core 
competences and a code of practice have been produced for European health professionals 20 33, based 
on research by Skirton et al. 34 and approved by the European Society of Human Genetics 35.  To date such 
recommendations are based on the subjective views of professionals, rather than evidence-based, data on 
user experience.  More recently, the US National Society of Genetic Counselors launched a series of new 
Evidence-Based Clinical Practice Guidelines although up to now these do not include RCDs, only Fragile 
X Syndrome and Down Syndrome. (http://www.nsgc.org/practiceguidelines). 
 
Service quality for RCD cases will inevitably be influenced by the availability of genetic specialist expertise.  
In this respect, the UK appears to be fortunate, with a higher number of genetic counsellors/nurses per 
million population than other European countries 32.  The existence of a long-established Rare 
Chromosome Disorder Support Group also differentiates the UK from other countries.  As the rates of RCD 
diagnoses rise significantly, thanks to wider use of microarray analyses and the anticipated introduction of 
next generation DNA sequencing into routine clinical practice, combined with the fact that RCD cases are 
inevitable geographically widespread, the role of non-geneticist clinicians will inevitably continue at various 
stages of the patient journey, reinforcing the need for common guidelines, multidisciplinary teamwork, audit 
checklists, training and coordinated care pathways 36 37 38. 
 
We recognise that the genetic and genomic testing and service landscape in the UK is also developing at 
a tremendous pace, not least because of the 100,000 Genomes project 39, the creation of 13 Genomic 
Medicine Centres across the UK 40, the Genomics England Clinical Interpretation Partnerships (GeCIP), 
designed to improve the accuracy and reliability of information fed back to patients 39; and a drive by Health 
Education England to educate non-genetics healthcare and other professionals in genomic medicine 41.  It 
is therefore imperative that the value of the expertise of UK families affected by RCDs is not lost in the 
rapid pace of developments in genomics per se for identifying current and future needs.  Although patients' 
and professionals' views may differ, there does appear to be a level of consensus on important domains 
such as: decision-making, knowledge of the genetic condition, perceived personal control, risk perception, 
diagnostic accuracy, and satisfaction/ quality of life 42.  Also, since clinical genetics services in the UK are 
currently delivered through a network of 23 centres, this network could facilitate the introduction of a 
coordinated strategy to support these families, although there is currently no designated centre of 
excellence specific to RCDs to take the lead.  It is possible that an holistic RCD-specific service might be 
introduced by the newly-emerging rare disease centres, such as those in Birmingham 43 and London 44.   
 
Our study inevitably has a number of limitations that should be borne in mind when considering the findings 
and subsequent recommendations.  Firstly, some bias in responses is likely as participants were recruited 
from a specialist support group and therefore respondents may be different from other UK families with an 
RCD child.  Secondly, it is possible that parents in Unique may be more knowledgeable because they are 
part of a well-established support group and have higher expectations (e.g. in terms of the information 
required) than people who do not belong to such an organisation.  Thirdly, although the greatest care was 
taken in questionnaire design, the validity and reliability of the data cannot be tested independently, as 
with all surveys which record individuals’ views19.  Finally, there may be recall inaccuracy since, in some 
instances, the survey requested information from families sometime after the event.  
 
Conclusions & Recommendations: 
These surveys of Unique members address the lack of data on genetic diagnosis and counselling care 
pathways experienced by families of children with RCDs.  Recommendations are offered in the spirit of 
constructive collaboration to assist clinicians to best meet the needs of patients and their families 21.  The 
findings set baseline data for the experiences of families in 2003 and 2013.  The intention is to repeat the 
surveys in 2018/2019 to gather patient-reported experiences as the new streamlined genetics service 
configuration is rolled out across the UK, and then again in 2021/2022 when new genetics services and 
implementation plans for the rare disease strategy are well embedded in the UK service provision.  We 
consider that establishment of this form of longer term overview of user experience is particularly important, 
not least because diagnoses and genetic counselling are likely to be increasingly provided by non-
geneticist clinicians. 
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Figure 1 Rating of Genetic Counselling Services 
 
Figure 1a: Q3.29 How helpful has the genetic counselling service been since your first 
appointment [%] 
 
 
 
 
Figure 1b: Q3.32 Overall, how would you rate the service you received from the geneticist(s)** 
on a scale from 1 (worst) to 10 (best) [Mean Score] 
 
 
 
** Genetic specialists include: Medical geneticist, Genetic nurse, Genetic counsellor 
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Table 1: Questionnaire Content for Stages 1-7 in the Patient Journey 
 
Stages 1-7 
 
Areas Covered in Questionnaire 
Stage 1:Pre-testing 
process 
1.1 Whether family was warned that their child's chromosomes were going to be tested. 
 
Stage 2: Test result 
communication 
 
2.1 How the diagnosis was communicated e.g. in person, by letter, by telephone etc. 
2.2 Which professional communicated the result e.g. paediatrician, medical geneticist, genetic counsellor, genetic nurse, general 
practitioner (GP), health visitor, obstetrician, other. 
2.3 Where the respondent was when informed about the test result e.g. in genetics centre, at child development centre, on 
postnatal ward, on children’s ward, at home, at work, in surgery/doctor’s room. 
2.4 The time of day, level of privacy and support when result was communicated e.g. whether during the day/evening/weekend, 
in public/private, on their own or with a spouse or partner/relative or friend present. 
 
Stage 3: Referral to a 
genetics specialist  
 
3.1 Whether the family was referred to a genetic specialist and, if referred, the waiting time to consultation. 
 
Stage 4: Conduct of 
genetics consultation 
4.1 Conduct of consultation with genetic specialist. 
4.2 Whether a written summary was provided following the consultation. 
 
 
Stage 5: Genetic and 
clinical information 
provision 
 
5.1 Genetics information provided about the chromosome disorder e.g. chromosome number(s) involved, type of disorder, full 
karyotype. 
5.2 Clinical information provided about the disorder e.g. its rarity, possible effects and details of similar cases. 
5.3 Whether a copy of the cytogenetics lab report was provided and, if not, whether respondent would have liked a copy. 
 
Stage 6: Genetics 
service follow-up 
 
6.1 Whether a follow-up appointment with a genetics professional was provided. 
6.2 Whether the family was informed about how the genetics service could help them in the future. 
 
Stage 7: Sign-posting 
to peer support 
 
 
7.1 Whether the family was given information about support groups. 
7.2 Whether families were encouraged to contact other families similarly affected. 
 
 
 
  
 
 
 
Table 2: Patient Journey - Questionnaire Responses (2003 – 2013) 
 
 
  Question: Information Requested 
 
No. 
Respondents 
 
2003 
 
2013 
Test for 
difference 
between 
percentages 
(P-value) 
 
Direction 
of Change* 
2003 2013 Frequency 
(N) 
Percentage 
(95% CI) 
Frequency  
(N) 
Percentage 
(95% CI) 583 575 
1. Warned child’s chromosomes to be tested 474 396 335 70.7 (66.4, 74.7) 290 73.2 (68.6, 77.5) 0.404 NS 
2. Results reported by paediatrician 543 447 350 64.5 (60.3, 68.5) 219 49.0 (44.3, 53.7) <0.001 Decr. 
3. Results reported by genetic specialist** 543 447 129 23.8 (20.2, 27.5) 201 45.0 (40.3, 49.7) <0.001 Incr. 
4. How respondent told result - in person 557 467 424 76.1 (72.4, 79.6) 293 62.7 (58.2, 67.1) <0.001 Decr. 
5. How respondent told result - by telephone 557 467 68 12.2 (9.6, 15.2) 103 22.1 (18.4, 26.1) <0.001 Incr. 
6. Place where told - at home 527 416 90 17.1 (14.0, 20.6) 113 27.1 (22.9, 31.7) <0.001 Incr. 
7. Place– genetics centre 527 416 46 8.7 (6.5, 11.5) 60 14.4 (11.1, 18.2) 0.006 Incr. 
8. Place– ward after birth/ children’s ward 527 416 150 28.5 (24.6, 32.5) 61 14.7 (11.4, 18.4) <0.001 Decr. 
9. How told result – in private 520 436 417 80.2 (76.5, 83.5) 354 81.1 (77.2, 84.8) 0.697 NS 
10. When told result – on your own 520 436 120 23.1 (19.5, 26.9) 122 28.0 (23.8, 32.4) 0.082 NS 
11. When told result – affected child/ren present 520 436 246 47.3 (42.9, 51.7) 201 46.1 (41.3, 50.9) 0.710 NS 
12. Family received genetic counselling 567 556 331 58.4 (54.2, 62.5) 289 52.0 (47.7, 56.2) 0.031 Decr. 
13. Not offered referral to clinical geneticist*** 412 296 92 22.3 (18.4, 26.7) 57 19.3 (14.9, 24.2) 0.322 NS 
14. Mean time referral to first meeting (days)# 308 279 na 95.7 (83.6, 107.7) na 115.0 (94.4, 135.7) 0.105 Incr. 
15. Family told in sensitive manner 519 437 347 66.9 (62.6, 70.9) 324 74.1 (69.8, 78.2) 0.014 Incr. 
16. Family not given enough information when told 517 440 359 69.4 (65.2, 73.4) 283 64.3 (59.6, 68.8) 0.093 NS 
17. Explanation of chromosome numbers involved 498 425 391 78.5 (74.6, 82.0) 354 83.3 (79.4, 86.7) 0.067 NS 
18. Type of chromosome disorder explained 498 425 285 57.2 (52.8, 61.6) 319 75.1 (70.7, 79.1) <0.001 Incr. 
19. Not offered further meeting after diagnosis 517 434 182 35.2 (31.1, 39.5) 134 30.9 (26.6, 35.5) 0.158 NS 
20. Family signposted to peer support group## 475 410 161 33.9 (29.6, 38.3) 254 62.0 (57.0, 66.7) <0.001 Incr. 
         
*     Direction of change. ‘Incr.’ = Significant Increase (p<0.05); ‘Decr.’ = Significant Decrease (p<0.05). ‘NS’ = No significant change (p>0.05). 
**   Genetic specialists include Medical geneticist, Genetic nurse, Genetic counsellor 
***  Families informed about result by a non-genetic specialist (e.g. paediatrician), not offered referral to a clinical geneticist. 
#     Percentage column in this row equals mean time in days. 
##    By medical geneticist 
 
 
 
Table 3: Study Recommendations vs NHS England Service Specification, and Levels Achieved. 
Stage Study Recommendation [Link***] 
 
In** %* 
a) Pre-test Robust procedure, including written, accessible information, to ensure that families are fully informed and truly understand when they consent to their child 
being referred for genetic testing [1] 
Y 73 
Robust procedure, including parents being give information on the possible results from genetic testing including the risk of a non-informative result [1] Y 73 
Non-genetics clinicians should be educated to recognise when the child's symptoms, including developmental delay, ID, clinical symptoms, behavioural issues 
etc. indicate that a rare chromosome disorder is a possibility and that genetic testing is appropriate [2, 3] 
Y na 
Non-clinical professionals, e.g. social workers, educators, should be educated to the possibility of a rare  chromosome disorder to explain a child's/family's 
difficulties & to know when to refer families on to a relevant clinician for appropriate assessment for genetic testing [2, 3] 
N - 
b) Testing Genetic testing should be done as quickly as possible, reducing the diagnostic odyssey for these families [14] N - 
Parents should be informed how long the results will take to come back & why there might be delays e.g. need for further analysis [1] N - 
c) Results Results should be given by a geneticist/competent non-geneticist clinician who fully understands the results & their interpretation & possible implications [2, 3] Y na 
Results should ideally be given face to face with the parents [4-11] Y 63 
Parents' preferences for the means by which the results are given to them should be ascertained at the time of testing [4-11] N - 
Results should only ever be given by telephone with the parents' express permission [4-11] N - 
Results should never be first revealed in a letter or email, unless requested specifically by parents [4-11] N - 
Results should be given in private, either in the clinician's office or at the family home [4-11] N - 
Results should ideally be given when both parents are present or if only one parent is available that they be accompanied by a relative or friend for support [4-11] N - 
Results should be given to parents without the affected child or other children present [4-11] N - 
d) Referral If pathogenic or likely-pathogenic results given by non-geneticist clinician, parents should be offered referral to a clinical geneticist/genetic counsellor [12,13] Y 80 
Parents should be informed of the waiting time for their appointment with a geneticist [14] N - 
Waiting times to see a geneticist should be kept to a minimum to reduce the isolation and anxiety of parents [14] N - 
e)Consultation Clinicians should offer the family accessible information about the child's disorder and a prognosis wherever possible e.g. a disorder-specific guide from the 
Unique website with a clear explanation of any technical/medical terms [16-18] 
Y 36 
Clinicians should explain the implications of the diagnosis on parents, siblings and the affected child's future reproductive risks and options, including 
information on how to explain the diagnosis to the child  and siblings where appropriate and how to make sure future genetic counselling is offered [16-18] 
Y 36 
All consultations should be conducted in a sensitive, empathetic manner, avoiding jargon and without being rushed [15] N - 
Clinicians should introduce themselves to parents and explain how long the consultation will last [15] N - 
Parents should be asked what information, if any, they already have about their child's diagnosis and how detailed they want information to be [16 -18] N - 
Clinicians should be sure to know at least basic information about the child and the family on first meeting to put the families at ease [15] N - 
Clinicians should explain what will happen in consultation, preferably providing families with clear written information beforehand about what to expect [15, 16] N - 
f) Follow-up Results should be documented in follow-up letter to parents written in accessible language with a copy of the genetics laboratory report for future reference [16] Y 36 
Parents should be referred to a reputable support organisation such as Unique for ongoing support, information and networking [20] Y 59 
Clinicians should offer follow-up meeting if appropriate and/or inform how to contact genetics service with further questions/ need for referral in future [19] Y 69  
Clinicians should explain what parents can expect from the genetic counselling service in future and any further practical support the service can offer e.g. 
letters of support explaining the child's disorder to support education/social services/benefits applications [19] 
Y 69 
Link*** = Question number(s) [1-20] in Table 1 linked to each recommendation. 
In** = Whether recommendation currently included (Y/N) in NHS England service specification for organisations funded to provide specialised medical genetics services.  
%* = % respondents reporting this was achieved (2013 survey). 
 
 
 
Supplementary file 1 – Survey Design 
 
Surveys are designed to explore attitudes, knowledge and behaviours to describe population views 
and trends.  The present surveys come under the category of descriptive surveys where the aim is to 
explore what is salient to survey participants.  Such an approach can provide useful information about 
social life and services delivery (Bowling, 2009).   
 
In terms of the Unique survey, questions to be included were initially designed by a team of parents 
drawn from families with RCD(s) and based on matters identified as important to them.  Many of 
these aspects had been highlighted anecdotally by thousands of families registered through Unique’s 
helpline from 1984 to 2003.  This is important because, although it is generally not possible to assess 
validity with a survey, the survey tool will have face validity if respondents recognise questions as 
pertaining to their experiences. 
 
Following this stage, the actual design of the survey tool was considered very carefully.  Questions 
were designed and set out to try to maximise useful responses.  Careful thought was given to mapping 
the design - using a mix of closed-ended questions and open responses, and using different formats 
across the survey in order to maximise question completion (Tourangeau, Rips, Rasinski, 2000). 
 
Open response questions were included to provide qualitative data to complement the quantitative 
data provided by closed-ended questions (reported in the current article).  While quantitative analysis 
of closed question responses can provide focused and highly generalizable information, qualitative 
data are particularly useful in obtaining an understanding of more subjective and personal aspects 
(Biggerstaff 2012). 
 
A pilot version of the questionnaire was created which was then trialled by 10 Unique member 
families plus the core Unique team, along with professional advisors highly experienced in design of 
questionnaires and of clinical genetics practice. 
 
Following minor revisions, the final questionnaire was disseminated to all relevant UK member 
families in Unique. 
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